

3

Docket No. GJE-73D1

Serial No. 10/667,721

In the Claims:

1 (Currently amended). A pro-apoptotic composition comprising a pharmaceutically acceptable diluent or carrier, and an excretory-secretory product, ~~isolatable from *Necator americanus*, ~~capable of inducing~~~~ wherein said product is less than 12 kDa and induces apoptosis in reactive T-cells.

2 (Currently amended). A method for treating cancer wherein said method comprises administering, to a mammal in need of such treatment, an effective amount of an excretory-secretory product isolatable from *Necator americanus*, ~~capable of inducing~~ wherein said product is less than 12 kDa and induces apoptosis in reactive T-cells.

3 (Original). The method, according to claim 2, wherein said mammal is a human.

4 (Currently amended). A method for treating inflammation wherein said method comprises administering, to a mammal in need of such treatment, an effective amount of an excretory-secretory product ~~isolatable from *Necator americanus*, ~~capable of inducing~~~~ wherein said product induces apoptosis in reactive T-cells.

5 (Original). The method, according to claim 4, wherein said mammal is a human.

6 (Currently amended). A substantially biologically pure excretory-secretory product, ~~isolatable from *Necator americanus*, ~~capable of inducing~~~~ wherein said product is less than 12 kDa and induces apoptosis in reactive T-cells.

J:\sh-resp\gje\gje2\GJE-73D1-2Amend.doc\DNB\la